APTARGROUP, INC. Q3 FY2026 earnings call

• Leadership Transition: Gael Touya introduced as new CEO, emphasizing 'Profitable Growth, Execution, and Discipline Capital Allocation.' Virginie Maes appointed President of Aptar Pharma effective Jan 1, 2027.
• Pharma Pipeline & Innovation: Strong focus on diversification beyond single products. Key developments include 'Beat the Blink' ophthalmic tech with Bausch & Lomb, collaborations with Massachusetts General Hospital (nose-to-brain delivery) and Macquarie University (biologics inhalers), and acquisition of Pulmonary’s Colibri technology. Biologics delivery beyond injectables is a major growth avenue.
• Operational Challenges in Beauty: North America beauty operations underperforming regarding profitability. Management acknowledges the need for 'execution with discipline and accountability,' noting it is a transformation requiring time, not a quick fix. Europe and Asia remain within long-term targets.
• Closures Momentum: Strong demand in beverage dispensing and conversion of tub-based condiments to pouches (e.g., Hormel Foods). Partnership with McCormick for spice closures continues.
• Manufacturing & Supply Chain: Expanded pharma operations in Mumbai, India. Launched 'Premier Precision' quality standard for elastomeric components. Collaborated with Stevanato Group for system-level injectable solutions.
• Russian Subsidiary: Deconsolidated Russian subsidiary (closures) effective Sept 21, 2026, due to loss of administrative control. Recorded a $61.2 million pre-tax charge ($0.94 per diluted share), excluded from adjusted earnings.

Pharma: Core sales increased 1% (8% excluding emergency medicine headwinds). Revenue contribution not explicitly stated in absolute terms for the segment alone, but total reported sales were just over $1 billion. Adjusted EBITDA margin was 36.4%. Beauty: Core sales increased 8%, driven by prestige fragrance and color cosmetics. Adjusted EBITDA margin declined to 11.4% due to North American operational challenges. Closures: Core sales increased 11%, driven by beverage (+19%) and food (+9%). Adjusted EBITDA margin was 15.5%, negatively impacted by indexation pass-throughs; without this impact, margins would have improved.

• Q4 2026 EPS: Expected range of $1.39 to $1.47, implying ~17% growth at midpoint vs. prior year Q4 (currency-neutral).
• Full Year 2026 CapEx: Maintained guidance of $260–$280 million.
• Full Year 2026 D&A: Maintained guidance of $310–$320 million.
• Tax Rate: Anticipated effective tax rate for Q4 is 17.5%–19.5%; long-term target remains 21%–23%.
• Exchange Rates: Guidance assumes EUR/USD rate of 1.12.

• Emergency Medicine Destocking: Significant headwind from Naloxone inventory reduction (~$65M full-year impact). Market dynamics shifting from prescription to OTC/generic may result in lower future growth rates despite GDP+ volume expectations.
• North America Beauty Margin Pressure: Structural issues in North American beauty operations leading to below-target margins. Improvement timeline is uncertain and non-linear.
• Regulatory & Compliance: Heavy reliance on regulatory approvals for pipeline products. Quality and safety compliance are critical differentiators and operational risks.
• Geopolitical: Loss of control over Russian subsidiary resulting in significant financial charge and deconsolidation.

Q: Analyst asked about the trajectory of emergency medicine destocking and whether residual impacts will persist into 2027.

A: CEO confirmed the $65M negative impact is tracking as planned and will lap in Q4. However, he noted that post-destocking growth rates for Naloxone will likely be lower than historical highs due to the structural shift from prescription to OTC/generic markets. Visibility on the new baseline will improve by Q1 2027.

Q: Analyst inquired if the long-term 7-11% growth corridor for Pharma has room for upward revision given strong intranasal market trends.

A: CEO expressed confidence in the 7-11% corridor, citing a robust pipeline across CNS, respiratory, and biologics. He emphasized that while quarterly results may fluctuate, the breadth of therapeutic areas supported reduces dependency on any single blockbuster drug.

Q: Analyst questioned specific actions to improve profitability in the underperforming North American beauty segment.

A: CEO admitted dissatisfaction with NA performance but highlighted completed diagnostics and a clear plan focused on execution discipline, quality improvement, and supply chain agility. He stressed this is a multi-year transformation, not a quick fix, requiring a cultural shift similar to the high-compliance standards in Pharma.

Q: Analyst sought clarity on the timing and revenue generation expectations for the Stephan Otto joint venture.

A: CEO described the partnership as key for integrated stability testing and validation solutions. While specific revenue timing wasn't detailed, he indicated strong market traction and satisfaction with the profile the JV offers customers for complex therapies.

Q: Analyst asked about gross margin trends and seasonality for Q4 2026.

A: CFO clarified that while margins improved sequentially in Q3, Q4 typically sees seasonal softness obscured recently by emergency medicine effects. She expects Q4 margins to reflect this seasonality but affirmed that the overall EPS guidance incorporates these factors, with underlying portfolio strength supporting growth.